摘要
目的探讨利司那肽联合贝那普利治疗对代谢综合征患者血糖血压、肠道微生态、靶器官损害的影响。方法选取2020年6月—2022年5月126例代谢综合征,根据治疗方法的不同均分为贝那普利组、利司那肽组和联合组,分别予贝那普利、利司那肽、贝那普利联合利司那肽治疗。统计3组治疗前后血糖、血压、肠道微生态指标、靶器官损害及不良反应发生情况。结果治疗6个月后,空腹血糖、餐后2 h血糖、糖化血红蛋白联合组<利司那肽组<贝那普利组,舒张压、收缩压联合组<贝那普利组<利司那肽组(P<0.05);治疗6个月后,乳酸杆菌、双歧杆菌、酵母菌联合组高于利司那肽组、贝那普利组,肠杆菌联合组低于利司那肽组、贝那普利组(P<0.05);治疗6个月后,联合组靶器官损害总发生率低于利司那肽组、贝那普利组(P<0.05);利司那肽组、贝那普利组肠道微生态指标、靶器官损害总发生率比较差异无统计学意义(P>0.05);3组不良反应总发生率比较差异无统计学意义(P>0.05)。结论利司那肽联合贝那普利治疗有利于调节代谢综合征患者肠道微生态,降低血压、血糖,减少靶器官损害发生,且安全可靠。
Objective To investigate the effects of Risinatide combined with Benazepril on blood glucose,blood pressure,intestinal microecology and target organ damage(TOD)in patients with metabolic syndrome.Methods In total,126 patients with metabolic syndrome from June 2020 to May 2022 were selected and divided into Benazepril group,Risinatide group and combination group according to different treatment methods,and were respectively treated with Benazepril,Risinatide,and Benazepril combined with Risinatide.Blood glucose,blood pressure,intestinal microecological indexes,TOD and adverse reactions were analyzed before and after treatment in the three groups.Results At 6 months after treatment,fasting blood glucose,2 h postprandial blood glucose,glycated hemoglobin in combination group were the lowest,followed by Lisenatide group and Benazepril group,and diastolic blood pressure and systolic blood pressure were the lowest in combination group,followed by Benazepril group and Lisenatide group(P<0.05).At 6 months after treatment,Lactobacillus,bifidobacterium and yeast were higher in combination group than in Risinatide group and Benazepril group,while enterobacter was lower in the combination group than in Risinatide group and Benazepril group(P<0.05).At 6 months after treatment,the total incidence of TOD in combination group was lower than that in Risinatide group and Benazepril group(P<0.05).There was no significant difference in intestinal microecological indexes and the total incidence of TOD between Lisinatide group and Benazepril group(P>0.05).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion Risinatide combined with Benazepril is safe and reliable for regulating intestinal microecology,lowering blood pressure and blood glucose,and reducing TOD in patients with metabolic syndrome.
作者
张玉红
宋凤莲
陈勇
ZHANG Yuhong;SONG Fenglian;CHEN Yong(Department of Infection Management,the People's Hospital of Jianyang City,Jianyang,Sichuan 641400,China)
出处
《临床误诊误治》
CAS
2023年第10期96-100,共5页
Clinical Misdiagnosis & Mistherapy
基金
四川省卫生和计划生育委员会(18PJ359)。
关键词
代谢综合征
贝那普利
利司那肽
空腹血糖
血压
肠道微生态
靶器官损害
药物毒性
Metabolic syndrome
Benazepril
Lisenatide
Fasting blood glucose
Blood pressure
Intestinal microecology
Target organ damage
Drug toxicity
